Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

atogepant

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

- PMLiVE

AbbVie: UK patients want better arthritis care

Study from Humira manufacturer concludes that UK doctors need better collaboration with patients

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

- PMLiVE

BMS’ Orencia matches Humira in arthritis study

Data should help drug establish itself against AbbVie's market-leading RA medicine

- PMLiVE

AbbVie gets ‘breakthrough’ status for hepatitis C regimen

Combination could be all-oral alternative to injectable interferon alpha-based therapies

- PMLiVE

Court blocks EMA release of pharma company data

AbbVie and InterMune successfully challenge request for trial data for Humira and Esbriet

- PMLiVE

AbbVie said to be planning major salesforce cuts in US

Follows loss of patent protection for TriCor and Niaspan

- PMLiVE

AbbVie sues EMA to block Humira data release

Pharma company seeks injunction following FOI requests for raw data

- PMLiVE

AbbVie expects Humira to drive growth in inaugural guidance

First statement since split from Abbott

- PMLiVE

Matt Regan named AbbVie’s general manager in UK

Was formerly general manager of Abbott in Norway

- PMLiVE

Abbott completes split as AbbVie debuts on NYSE

New company will focus on research-based pharmaceuticals

- PMLiVE

Abbott cuts 550 jobs as Q3 sales stay flat

Layoffs come as company prepares to spin off its pharma division as AbbVie

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links